Back Article

Siegel RL, Miller KD, Wagle NS, Jemal A. 2023. Cancer statistics, 2023. CA: A Cancer Journal for Clinician 73:17−48

Ferlay J, Partensky C, Bray F. 2016. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncologica 55:1158−60

Kolbeinsson HM, Chandana S, Wright GP, Chung M. 2023. Pancreatic cancer: a review of current treatment and novel therapies. Journal of Investigative Surgery 36:2129884

Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, et al. 1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology 15:2403−13

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, et al. 2011. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine 364:1817−25

Von Hoff DD, Ervin T, Arena FP, Gabriela Chiorean E, Infante J, et al. 2013. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine 369:1691−703

Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, et al. 2013. Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma. Pancreas 42:1311−15

Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, et al. 2023. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. The Lancet 402:1272−81

Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, et al. 2020. Metastatic pancreatic cancer: ASCO guideline update. Journal of Clinical Oncology 38:3217−30

Taieb J, Prager GW, Melisi D, Westphalen CB, D'Esquermes N, et al. 2020. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. ESMO Open 5:e000587

Latenstein AEJ, van der Geest LGM, Bonsing BA, Groot Koerkamp B, Haj Mohammad N, et al. 2020. Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. European Journal of Cancer 125:83−93

Pijnappel EN, Dijksterhuis WPM, van der Geest LG, de Vos-Geelen J, de Groot JWB, et al. 2021. First- and second-line palliative systemic treatment outcomes in a real-world metastatic pancreatic cancer cohort. Journal of the National Comprehensive Cancer Network 20:443−450.e3

Boyne DJ, Brenner DR, Gupta A, MacKay E, Arora P, et al. 2023. Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data. Annals of Epidemiology 78:28−34

Klein-Brill A, Amar-Farkash S, Lawrence G, Collisson EA, Aran D. 2022. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. JAMA Network Open 5:e2216199

Cartwright TH, Parisi M, Espirito JL, Wilson TW, Pelletier C, et al. 2018. Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting. Drugs - Real World Outcomes 5:149−59

Kang J, Hwang I, Yoo C, Kim KP, Jeong JH, et al. 2018. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Investigational New Drugs 36:732−41

Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, et al. 2018. Comparative effectiveness of nab-paclitaxel plus gemcitabine vs FOLFIRINOX in metastatic pancreatic cancer: a retrospective nationwide chart review in the United States. Advances in Therapy 35:1564−77

Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, et al. 2019. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Therapeutic Advances in Gastroenterology 12:1−14

Chun JW, Lee SH, Kim JS, Park N, Huh G, et al. 2021. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach. BMC Cancer 21:537

Martín AM, Hidalgo M, Alvarez R, Arrazubi V, Martínez-Galán J, et al. 2018. From first line to sequential treatment in the management of metastatic pancreatic cancer. Journal of Cancerr 9:1978−88

Liu Y, Guo X, Xu P, Song Y, Huang J, et al. 2024. Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study. Cancer Biology & Medicine 21:799−812

Ay S, Atcı MM, Arıkan R, Dülgar Ö, Özyükseler DT, et al. 2022. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer. Journal of Chemotherapy 34:465−71

Cho IR, Kang H, Jo JH, Lee HS, Chung MJ, et al. 2020. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. World Journal of Gastrointestinal Oncology 12:182−94

Franco F, Camara JC, Martín-Valadés JI, López-Alfonso A, Marrupe D, et al. 2021. Clinical outcomes of FOLFIRINOX and gemcitabine–nab paclitaxel for metastatic pancreatic cancer in the real world setting. Clinical and Translational Oncology 23:812−19

Park CS, Park BK, Han JH, Lee KJ, Son KJ. 2024. Real-world outcomes of first-line chemotherapy in metastatic pancreatic cancer: a nationwide population-based study in Korea. Cancers 16:3173

Mie T, Sasaki T, Takeda T, Okamoto T, Hamada T, et al. 2023. Treatment outcomes and prognostic factors of gemcitabine plus nab-paclitaxel as second-line chemotherapy after modified FOLFIRINOX in unresectable pancreatic cancer. Cancers 15:358

Chae H, Jeong H, Cheon J, Chon HJ, Ryu H, et al. 2020. Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. Therapeutic Advances in Medical Oncology 12:1−8

Chiorean EG, Cheung WY, Giordano G, Kim G, Al-Batran SE. 2019. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review. Therapeutic Advances in Medical Oncology 11:1−17

Pusceddu S, Ghidini M, Torchio M, Corti F, Tomasello G, et al. 2019. Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis. Cancers 11:484

Chen J, Hua Q, Wang H, Zhang D, Zhao L, et al. 2021. Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer. BMC Cancer 21:853

Han SY, Kim DU, Seol YM, Kim S, Lee NK, et al. 2020. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer. World Journal of Clinical Casess 8:3718−29

Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, et al. 2015. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 26:v56−v68

Ohba A, Ozaka M, Ogawa G, Okusaka T, Kobayashi S, et al. 2023. 1616O: Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): a multicentred, randomized, open-label, three-arm, phase II/III trial. Annals of Oncology 34:S894